Opendata, web and dolomites

RARITY SIGNED

RAtional design of canceR ImmunoTherapY: one size does not fit all

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RARITY project word cloud

Explore the words cloud of the RARITY project. It provides you a very rough idea of what is the project "RARITY" about.

ground    minority    activate    selectively    cell    malignancies    antigens    patients    detect    deploying    events    translation    few    revolutionized    benefit    strategies    innovative    modulation    distinctive    shortcomings    screening    preliminary    rarity    15    ex    naturally    anti    lt    therapeutic    inventoried    solutions    blockade    mainly    applicability    thought    de    reactive    genomic    vivo    immune    regions    checkpoint    induce    demonstrates    cancer    natural    responds    treatment    isolation    activation    data    immunotherapy    transcription    compromised    employment    acquire    arise    fingerprint    treatments    cancers    detectable    play    provoking    therapy    therapies    lack    proteins    personalized    phenotypes    cytometry    mass    immunotherapies    mutations    imaging    complementary    tumour    immunogenic    technologies    conducting    benefits    categorised    vaccination    exomic    multidimensional    microenvironments    novo    suggest    breaking    diagnosed    unprecedented    unannotated    tissues    cells    class   

Project "RARITY" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 1˙499˙795 €
 EC max contribution 1˙499˙795 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2024-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 1˙499˙795.00

Map

 Project objective

Checkpoint blockade immunotherapies have revolutionized cancer treatment. However, this immunotherapy only benefits a minority of patients (< 15%), mainly those diagnosed with cancers having many mutations. Furthermore, checkpoint blockade therapy does not selectively activate cancer-reactive T cells. RARITY responds to these shortcomings, aiming to provide innovative solutions for the development of effective immunotherapies for patients who do not benefit from current treatments. The ground-breaking preliminary data included in this application demonstrates that cancer-reactive T cells can be naturally present in so-called non-immunogenic cancers and that they acquire distinctive phenotypes. RARITY will apply state-of-the-art technologies to fingerprint these phenotypes. This will allow the isolation of cancer-reactive T cells from tumour tissues and their employment as highly-effective therapies. Therapeutic vaccination with cancer antigens can also be used to induce T cell responses in patients where natural activation of cancer-specific T cells is not detectable. However, the applicability of vaccination is compromised by the lack of specific targets, particularly in malignancies with few mutations. RARITY will address this problem by deploying a novel class of cancer antigens. An unprecedented screening of non-exomic genomic regions will be done to detect unannotated proteins that arise from de novo transcription and translation events. These proteins can then be targeted by personalized immunotherapies. Finally, thought-provoking findings included in RARITY suggest that immune cell subsets other than T cells play a major role in anti-tumour immune responses. These subsets need to be fully inventoried and categorised so that complementary strategies to T cell immunotherapies can be developed. RARITY will do so by conducting multidimensional analysis of cancer microenvironments using imaging mass cytometry and ex vivo modulation of immune responses.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RARITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RARITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

ii-MAX (2020)

Unravelling new immunity-independent mechanisms for durable resistance to blast fungi using MAX effectors

Read More